The company says it will switch to a broader approach for its experimental drug, remdesivir. But it was overwhelmed by demand for a potential treatment promoted by President Trump.
Tag: Gilead Sciences Inc
Gilead to Expand Coronavirus Drug Trials to Other Countries
The drug maker said that in March it would begin two more clinical trials of remdesivir, an experimental antiviral drug, in more nations outside China.
Who Owns H.I.V.-Prevention Drugs? The Taxpayers, U.S. Says
In an unexpected lawsuit, federal officials claim that Gilead Sciences willfully disregarded government patents on medicines necessary to end the AIDS epidemic.
A Cure for Ebola? Two New Treatments Prove Highly Effective in Congo
The therapies saved roughly 90 percent of the patients who were newly infected, a turning point in the decades-long fight against the virus.
An Experimental Ebola Cure May Also Protect Against Nipah Virus
African green monkeys survived infection with the Nipah virus after they received remdesivir. The virus, a pandemic threat carried by bats, has killed dozens of people in Asia.
Global Health: Gilead Will Donate Truvada to U.S. for H.I.V. Prevention
The manufacturer will provide enough of the drug to supply 200,000 patients annually for more than a decade. Critics said it would not be enough to end the AIDS epidemic and questioned the company’s motives.
Global Health: Bit by Bit, Scientists Gain Ground on AIDS
The “London patient,” apparently cured of H.I.V. infection, has gotten all the attention. But other recently revealed advances are more likely to affect the immediate course of the AIDS epidemic.